◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksM › MRM

MEDIROM Healthcare Technologies Inc. (MRM) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Consumer Cyclical · Personal Services · DATA UPDATED 2026-09-08

MEDIROM Healthcare Technologies Inc. (MRM) operates in the Personal Services industry and is headquartered in Tokyo, Japan with about 334 employees. Its market capitalization is roughly $7 million. In the fiscal year ended 2024-12-31, MRM reported JPY 8.3B in revenue and JPY 149M in net income.

MEDIROM Healthcare Technologies Inc., together with its subsidiaries, provides holistic health services in Japan. It operates in three segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty.

Interactive charts & full statements → Open the MRM valuation workbench →

MRM Revenue & Earnings History — Annual Income Statement

Income statement2024-12-312023-12-312022-12-312021-12-31
Total RevenueJPY 8.3BJPY 6.8BJPY 7.0BJPY 5.4B
Gross ProfitJPY 2.2BJPY 1.6BJPY 1.9BJPY 1.4B
Operating Income (EBIT)JPY 19M(JPY 370M)JPY 118M(JPY 380M)
Net IncomeJPY 149MJPY 115MJPY 149M(JPY 991M)

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MRM Free Cash Flow History

MRM Balance Sheet History

Balance sheet2024-12-312023-12-312022-12-312021-12-31
Total AssetsJPY 8.1BJPY 6.8BJPY 6.7BJPY 5.8B
Total LiabilitiesJPY 6.9BJPY 6.6BJPY 6.8BJPY 6.0B

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MRM viewer.

Other Companies in Personal Services

← MRLNAll “M” companiesMRN →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.